EN9.F Enzymatica AB

Healthcare Drug Manufacturers - Specialty & Generic Frankfurt Exchange
0.1900 EUR
Close of Nov 11, 2026
0.1170 0.2800
Market cap
EUR 46.1M
P/E
-
P/B
5.36x
ROE
-43.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is EN9.F undervalued?

Graham number

The Graham number of Enzymatica AB cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Enzymatica AB fundamental analysis

No fundamental analysis for Enzymatica AB yet.

Enzymatica AB stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Enzymatica AB

Enzymatica AB (publ), a life science company, develops and sells medical devices for infectious diseases. The company's product includes ColdZyme, a mouth spray that protects against the upper respiratory viruses that can cause cold and flu symptoms. It also provides enzyme formulations for skin care under Penzyme technology. The company was incorporated in 2007 and is headquartered in Lund, Sweden.

Full company profile